Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience Corp., a pioneer in drug delivery platforms, is undergoing a significant transition as outgoing CEO Chris Bunka announces the company’s sharpened focus on pharmaceutical studies and industry collaborations, along with the appointment of new CEO Richard Christopher. The company has made substantial progress, including a successful IND filing with the FDA, and has seen its market capitalization soar from $5 million to $60 million within a year.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
